Compare Bristol-Myers Squibb Co (BMY) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Verizon Communications Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.82 (market cap $129.94B), while Verizon Communications Inc trades at $46.92 (market cap $196.40B). The key difference: Verizon Communications Inc is the larger of the two by market cap, and Verizon Communications Inc pays the higher dividend (5.99%). Which is the better fit depends on your goals.
| BMY | VZ | |
|---|---|---|
Market Cap | $129.94B | $196.40B |
Sector | Health | Media |
52-Week High | $65.89 | $51.38 |
52-Week Low | $42.60 | $38.40 |
Enterprise Value | $163.92B | $383.10B |
Dividend Yield | 3.96% | 5.99% |
Volume | — | 22,584,735 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Verizon (VZ) trades at $46.77, down 0.56% today, with a bullish technical signal from moving averages and a consensus analyst price target of $49.69. The company reported Q2 2026 EPS of $1.30, beating estimates, and maintains strong cash flow with $37.14B from operations in 2025. Recent news highlights partnerships, such as with Fi for pet tech integration, and network initiatives amid competitive pressures from SpaceX's Starlink.
Outlook: VZ offers value with a P/E of 12.31 and a 15.63% ROE, supported by stable dividends. Risks include rising debt to $298.5B in 2025 and revenue stagnation. Opportunities lie in fiber expansion and margin improvements, but investor caution is warranted due to competitive threats and macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
